CG Oncology Announces Successful Pricing of Public Offering
IRVINE, Calif. — CG Oncology, Inc. (Nasdaq: CGON), a pioneering clinical biopharmaceutical company dedicated to advancing treatments for bladder cancer, has recently announced the pricing for its public offering. This significant event is expected to bolster the company's mission of creating innovative and effective therapies that spare patients from the need for invasive procedures.
Details of the Offering
The public offering consists of 8,000,000 shares of common stock, with 7,300,000 shares being offered by CG Oncology and an additional 700,000 shares by an existing stockholder. Each share is priced at $28.00, which brings the gross proceeds from the offering to an impressive $204.4 million. However, it's important to note that CG Oncology will not receive any returns from the shares sold by the existing stockholder.
Expected Closing and Options for Underwriters
This offering is anticipated to close shortly, pending the fulfillment of standard closing conditions. To further enhance the offering, CG Oncology has granted underwriters the option to acquire an additional 1,200,000 shares within the next 30 days at the same public offering price adjusted for any applicable underwriting fees.
Co-Managing Underwriters
The offering is being orchestrated by leading financial institutions, including Morgan Stanley, Goldman Sachs, TD Cowen, and Stifel, who are stepping in as joint book-running managers. LifeSci Capital is also supporting the effort as the lead manager for this offering.
Accessing the Final Prospectus
A registration statement specific to this offering has been filed and authorized by the Securities and Exchange Commission (SEC). Interested parties can access the final prospectus via Morgan Stanley, Goldman Sachs, and other financial institutions involved. The prospectus provides further details regarding the offering and is essential for potential investors.
About CG Oncology
CG Oncology is committed to providing a future where patients affected by bladder cancer can access effective, bladder-sparing immunotherapy options. The company’s groundbreaking research aims to improve the lives of those facing urologic cancers. Their ongoing dedication towards creating advanced treatments positions them at the forefront of innovation within the biopharmaceutical industry.
Ongoing Commitment and Future Endeavors
As CG Oncology navigates this promising phase of growth and opportunity, they remain devoted to their core mission of enhancing the quality of life for bladder cancer patients. With the funds acquired through this offering, the company is poised to further its research and development strategies, potentially leading to new, groundbreaking therapies that prioritize patient health and comfort.
Impact on Patient Lives
Through their innovative approaches, CG Oncology seeks to change the landscape of bladder cancer treatment. The potential to develop therapies that prioritize patient outcomes aligns with CG Oncology’s mission, promising hope and improved quality of life for many.
Frequently Asked Questions
What is the total amount raised from the public offering?
CG Oncology raised approximately $204.4 million from the offering of 8,000,000 shares of common stock.
Who are the major underwriters for this offering?
The offering is managed by Morgan Stanley, Goldman Sachs, TD Cowen, and Stifel, with LifeSci Capital serving as the lead manager.
When is the expected closing date for the offering?
The offering is anticipated to close shortly, subject to customary closing conditions.
How will CG Oncology utilize the funds raised?
The funds will support CG Oncology’s mission to develop innovative bladder-cancer therapies, potentially advancing their research and treatment capabilities.
What is CG Oncology's core focus?
CG Oncology specializes in developing therapies designed to spare bladder cancer patients from invasive treatments while enhancing their quality of life.
